March 3, 2008
Alexza’s AZ-104 (Staccato® Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
February 25, 2008
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato® Loxapine)
March 26, 2007
Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
December 4 , 2006
Alexza Pharmaceuticals and Symphony Capital Enter into $50 Million Product Development Collaboration for AZ-002 and AZ-004

 

          

 

Symphony Allegro is supporting the advancement of AZ-004 through Phase III clinical trials for the treatment of acute agitation in patients with schizophrenia and bipolar disorder, AZ-104 through Phase IIa clinical trials for the treatment of migraine, and AZ-002 through Phase IIb clinical trials for the treatment of panic attack in patients with panic disorder.

Visit the Alexza Pharmaceuticals Website